The SH-SY5Y Cell Line in Parkinson's Disease Research: a Systematic Review

Overview

Journal Mol Neurodegener

Publisher Biomed Central

Specialties Molecular Biology
Neurology

Date 2017 Jan 26

PMID 28118852

Citations 359

Authors

Helena Xicoy

Be Wieringa

Gerard J M Martens

Affiliations

Soon will be listed here.

Abstract

Parkinson's disease (PD) is a devastating and highly prevalent neurodegenerative disease for which only symptomatic treatment is available. In order to develop a truly effective disease-modifying therapy, improvement of our current understanding of the molecular and cellular mechanisms underlying PD pathogenesis and progression is crucial. For this purpose, standardization of research protocols and disease models is necessary. As human dopaminergic neurons, the cells mainly affected in PD, are difficult to obtain and maintain as primary cells, current PD research is mostly performed with permanently established neuronal cell models, in particular the neuroblastoma SH-SY5Y lineage. This cell line is frequently chosen because of its human origin, catecholaminergic (though not strictly dopaminergic) neuronal properties, and ease of maintenance. However, there is no consensus on many fundamental aspects that are associated with its use, such as the effects of culture media composition and of variations in differentiation protocols. Here we present the outcome of a systematic review of scientific articles that have used SH-SY5Y cells to explore PD. We describe the cell source, culture conditions, differentiation protocols, methods/approaches used to mimic PD and the preclinical validation of the SH-SY5Y findings by employing alternative cellular and animal models. Thus, this overview may help to standardize the use of the SH-SY5Y cell line in PD research and serve as a future user's guide.

Citing Articles

Cell culture research in aging and Alzheimer's disease: The strategic use/reuse of untreated controls and savings people's tax dollars.

Kshirsagar S, Islam M, Reddy A, Reddy P J Alzheimers Dis Rep. 2025; 9:25424823241310716.

PMID: 40034533 PMC: 11864248. DOI: 10.1177/25424823241310716.

Resveratrol-Enhanced Human Neural Stem Cell-Derived Exosomes Mitigate MPP+-Induced Neurotoxicity Through Activation of AMPK and Nrf2 Pathways and Inhibition of the NLRP3 Inflammasome in SH-SY5Y Cells.

Chiang M, Yang Y, Nicol C, Chiang T, Yen C Life (Basel). 2025; 15(2).

PMID: 40003703 PMC: 11856727. DOI: 10.3390/life15020294.

Sub-network transcriptome dataset for diseases associated with exposure to bisphenol F and bisphenol S in human SH-SY5Y neuroblastoma cells.

Guzman A, Sanchez C, Ivantsova E, Watkins J, Sutton S, Souders 2nd C Data Brief. 2025; 59:111313.

PMID: 39968403 PMC: 11833777. DOI: 10.1016/j.dib.2025.111313.

Dopamine stabilized in ultra-nanoreservoirs for controlled delivery in parkinson's disease.

Padilla-Godinez F, Lopez-Goerne T, Calvillo-Munoz E, Alvarez-Lemus M, Navarrete-Bolanos J, Collazo-Navarrete O Nanomedicine (Lond). 2025; 20(6):543-557.

PMID: 39935342 PMC: 11881884. DOI: 10.1080/17435889.2025.2460228.

Repression of varicella zoster virus gene expression during quiescent infection in the absence of detectable histone deposition.

Wang J, Bruckner N, Weissmann S, Gunther T, Zhu S, Vogt C PLoS Pathog. 2025; 21(2):e1012367.

PMID: 39928684 PMC: 11838886. DOI: 10.1371/journal.ppat.1012367.

References

Exner N, Lutz A, Haass C, Winklhofer K . Mitochondrial dysfunction in Parkinson's disease: molecular mechanisms and pathophysiological consequences. EMBO J. 2012; 31(14):3038-62. PMC: 3400019. DOI: 10.1038/emboj.2012.170. View

Macchi F, Deleersnijder A, Van den Haute C, Munck S, Pottel H, Michiels A . High-content analysis of α-synuclein aggregation and cell death in a cellular model of Parkinson's disease. J Neurosci Methods. 2015; 261:117-27. DOI: 10.1016/j.jneumeth.2015.11.009. View

Hasegawa T, Matsuzaki M, Takeda A, Kikuchi A, Akita H, Perry G . Accelerated alpha-synuclein aggregation after differentiation of SH-SY5Y neuroblastoma cells. Brain Res. 2004; 1013(1):51-9. DOI: 10.1016/j.brainres.2004.04.018. View

Poulin J, Zou J, Drouin-Ouellet J, Kim K, Cicchetti F, Awatramani R . Defining midbrain dopaminergic neuron diversity by single-cell gene expression profiling. Cell Rep. 2014; 9(3):930-43. PMC: 4251558. DOI: 10.1016/j.celrep.2014.10.008. View

Mazzio E, Soliman K . Pyruvic acid cytoprotection against 1-methyl-4-phenylpyridinium, 6-hydroxydopamine and hydrogen peroxide toxicities in vitro. Neurosci Lett. 2003; 337(2):77-80. DOI: 10.1016/s0304-3940(02)01327-7. View

Simola N, Morelli M, Carta A . The 6-hydroxydopamine model of Parkinson's disease. Neurotox Res. 2007; 11(3-4):151-67. DOI: 10.1007/BF03033565. View

Hegarty S, Sullivan A, OKeeffe G . BMP2 and GDF5 induce neuronal differentiation through a Smad dependant pathway in a model of human midbrain dopaminergic neurons. Mol Cell Neurosci. 2013; 56:263-71. DOI: 10.1016/j.mcn.2013.06.006. View

Teppola H, Sarkanen J, Jalonen T, Linne M . Morphological Differentiation Towards Neuronal Phenotype of SH-SY5Y Neuroblastoma Cells by Estradiol, Retinoic Acid and Cholesterol. Neurochem Res. 2015; 41(4):731-47. PMC: 4824837. DOI: 10.1007/s11064-015-1743-6. View

Dexter D, Jenner P . Parkinson disease: from pathology to molecular disease mechanisms. Free Radic Biol Med. 2013; 62:132-144. DOI: 10.1016/j.freeradbiomed.2013.01.018. View

10.

Wang H, Imai Y, Kataoka A, Takahashi R . Cell type-specific upregulation of Parkin in response to ER stress. Antioxid Redox Signal. 2007; 9(5):533-42. DOI: 10.1089/ars.2006.1522. View

11.

Encinas M, Iglesias M, Liu Y, Wang H, Muhaisen A, Cena V . Sequential treatment of SH-SY5Y cells with retinoic acid and brain-derived neurotrophic factor gives rise to fully differentiated, neurotrophic factor-dependent, human neuron-like cells. J Neurochem. 2000; 75(3):991-1003. DOI: 10.1046/j.1471-4159.2000.0750991.x. View

12.

Yang H, Wang J, Sun J, Liu X, Duan W, Qu T . A new method to effectively and rapidly generate neurons from SH-SY5Y cells. Neurosci Lett. 2015; 610:43-7. DOI: 10.1016/j.neulet.2015.10.047. View

13.

Kahns S, Lykkebo S, Jakobsen L, Nielsen M, Jensen P . Caspase-mediated parkin cleavage in apoptotic cell death. J Biol Chem. 2002; 277(18):15303-8. DOI: 10.1074/jbc.M111534200. View

14.

Battich N, Stoeger T, Pelkmans L . Control of Transcript Variability in Single Mammalian Cells. Cell. 2015; 163(7):1596-610. DOI: 10.1016/j.cell.2015.11.018. View

15.

Dorsey E, Constantinescu R, Thompson J, Biglan K, Holloway R, Kieburtz K . Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology. 2006; 68(5):384-6. DOI: 10.1212/01.wnl.0000247740.47667.03. View

16.

Grimm J, Mueller A, Hefti F, Rosenthal A . Molecular basis for catecholaminergic neuron diversity. Proc Natl Acad Sci U S A. 2004; 101(38):13891-6. PMC: 518849. DOI: 10.1073/pnas.0405340101. View

17.

Nonaka T, Hasegawa M . A cellular model to monitor proteasome dysfunction by alpha-synuclein. Biochemistry. 2009; 48(33):8014-22. PMC: 2728579. DOI: 10.1021/bi900619j. View

18.

Storch A, Kaftan A, Burkhardt K, Schwarz J . 6-Hydroxydopamine toxicity towards human SH-SY5Y dopaminergic neuroblastoma cells: independent of mitochondrial energy metabolism. J Neural Transm (Vienna). 2000; 107(3):281-93. DOI: 10.1007/s007020050023. View

19.

Buttiglione M, Vitiello F, Sardella E, Petrone L, Nardulli M, Favia P . Behaviour of SH-SY5Y neuroblastoma cell line grown in different media and on different chemically modified substrates. Biomaterials. 2007; 28(19):2932-45. DOI: 10.1016/j.biomaterials.2007.02.022. View

20.

Alves da Costa C, Dunys J, Brau F, Wilk S, Cappai R, Checler F . 6-Hydroxydopamine but not 1-methyl-4-phenylpyridinium abolishes alpha-synuclein anti-apoptotic phenotype by inhibiting its proteasomal degradation and by promoting its aggregation. J Biol Chem. 2006; 281(14):9824-31. DOI: 10.1074/jbc.M513903200. View